FIB-4 and the Silent Liver: Reading Fibrosis From Routine Blood Work

Key Takeaways:

• A normal ALT does not rule out serious liver disease: in a biopsy series of 51 people with fatty liver disease and normal ALT, 12 had bridging fibrosis and 6 had cirrhosis, and the full range of disease matched that seen with elevated ALT.
• In 541 adults with fatty liver disease, a FIB-4 index of 1.30 or below had a 90 percent negative predictive value for advanced fibrosis, and FIB-4 outperformed seven other simple noninvasive markers.
• FIB-4 performs poorly at age 35 or younger, and at 65 or older its specificity for advanced fibrosis falls to 35 percent; raising the cutoff to 2.0 in that age group lifted specificity to 70 percent while keeping sensitivity at 77 percent.

October is Liver Awareness Month, and the liver is the organ most likely to be quietly scarring while every routine number looks fine. Fibrosis is the liver’s version of a scar. When fat, alcohol, or a virus injures hepatocytes over years, stellate cells in the spaces around the sinusoids switch on and lay down collagen, and that collagen slowly bridges between the liver’s small vascular units until, at the far end, the architecture becomes cirrhosis. ALT, the enzyme most people think of as the liver test, reflects hepatocytes leaking their contents today. It says little about how much scar has already accumulated, and in a fatty, slowly scarring liver it can sit squarely in the normal range. In a biopsy series of 51 people with fatty liver disease and normal ALT, 12 had bridging fibrosis and 6 had cirrhosis, and the spread of disease was no different from people with elevated ALT. The FIB-4 index was built to see past that blind spot using numbers already on a standard lab report. It multiplies age by AST and divides by the platelet count times the square root of ALT. Each term carries information: age stands in for years of exposure, AST tends to rise relative to ALT as scar accumulates, and platelets drift down as a stiffening liver raises pressure in the portal circulation.

The index was derived in 2006 from liver biopsies in 832 patients with HIV and hepatitis C coinfection, where it separated mild from advanced fibrosis well enough that 71 percent of the validation group could have avoided a biopsy. It has since become the front door for fatty liver disease, now called metabolic dysfunction-associated steatotic liver disease, or MASLD. In a national database of 541 adults with fatty liver disease, FIB-4 outperformed seven other simple noninvasive markers, and a score of 1.30 or below carried a 90 percent negative predictive value for advanced fibrosis, while a score of 2.67 or above carried an 80 percent positive predictive value. The 2023 practice guidance from the American Association for the Study of Liver Diseases builds its screening pathway on exactly these numbers. It recommends targeted rather than general-population screening: calculating FIB-4 in people at higher risk, including those with type 2 diabetes, obesity with metabolic complications, a family history of cirrhosis, more than mild alcohol use, or fatty liver found on imaging. A score below 1.3 counts as low risk, and anything higher goes to a second test, usually a vibration-controlled liver stiffness measurement, with the ELF blood panel as an accepted alternative, rather than straight to biopsy.

Who should get a FIB-4 index check?

Anyone with fatty liver on an ultrasound, type 2 diabetes, obesity with other metabolic risk factors, a family history of cirrhosis, or more than light drinking is a reasonable candidate, and because the ingredients are already in a routine metabolic panel and blood count, the calculation itself costs nothing. The honest limits come from the formula’s own design. Because age sits in the numerator, the index behaves differently at the edges of adulthood. In a European multicenter biopsy study of 634 patients, FIB-4 performed poorly at age 35 or younger, and at 65 or older its specificity for advanced fibrosis fell to 35 percent, meaning a large share of older adults would be flagged falsely. Raising the cutoff to 2.0 in people 65 and older lifted specificity to 70 percent while keeping sensitivity at 77 percent. A low score also rules out advanced fibrosis rather than all liver disease, and a 90 percent negative predictive value is strong, not perfect. Scores between the low and high cutoffs are indeterminate and need that second test. And a FIB-4 is a snapshot; the guidance suggests repeating it every one to two years when metabolic risk factors persist. The quiet message of Liver Awareness Month is that a normal ALT is not a clean bill of liver health, and a two-minute calculation can tell the difference.

References:

1. Mofrad, P., Contos, M. J., Haque, M., Sargeant, C., Fisher, R. A., Luketic, V. A., et al. (2003). Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology, 37(6), 1286-1292.
2. Sterling, R. K., Lissen, E., Clumeck, N., Sola, R., Correa, M. C., Montaner, J., et al. (2006). Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology, 43(6), 1317-1325.
3. Shah, A. G., Lydecker, A., Murray, K., Tetri, B. N., Contos, M. J., & Sanyal, A. J. (2009). Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clinical Gastroenterology and Hepatology, 7(10), 1104-1112.
4. Rinella, M. E., Neuschwander-Tetri, B. A., Siddiqui, M. S., Abdelmalek, M. F., Caldwell, S., Barb, D., et al. (2023). AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology, 77(5), 1797-1835.
5. McPherson, S., Hardy, T., Dufour, J. F., Petta, S., Romero-Gomez, M., Allison, M., et al. (2017). Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis. The American Journal of Gastroenterology, 112(5), 740-751.